Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(46)
•••
Comment by greaterfoolFredon May 28, 2020 2:17pm
117 Views
Post# 31083831

RE:RE:RE:RE:RE:RE:Question? Does Anyone Wonder ....

RE:RE:RE:RE:RE:RE:Question? Does Anyone Wonder ....Thanks for the reply JD.  The consistency of your tone never fails to disappoint.   Perhaps you should have another think about my post.  Or maybe it would be better if I ‘splained it to you.  There are two central ideas;
  1. We need money and I suggested an offering to holders; this could be in the form of rights to purchase, for 5 cents, one share for each share already held.  Those who pony up would still own at least the same share of the company and perhaps more.  We could raise about 3 million.  Other companies have done this.
  2. We need proof of concept in NHPs to draw in new investors.  I’m not sure how to make this idea any simpler for you.  The payload should be impressive and hopefully useful, and the monkeys should not be harmed.
These are just ideas.  This forum would be much more useful if ideas were debated, not just belittled.  We may have better tech than Denali, but we have to demonstrate it.  Right now all of our eggs are in one basket.  We need more baskets.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities